Association between length of barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 11, 2013, Pages 1430-1436

  Anaparthy, Rajeswari ^a   Gaddam, Srinivas ^a   Kanakadandi, Vijay ^a   Alsop, Benjamin R ^a   Gupta, Neil ^a   Higbee, April D ^a   Wani, Sachin B ^a   Singh, Mandeep ^a   Rastogi, Amit ^a   Bansal, Ajay ^a   Cash, Brooks D ^b   Young, Patrick E ^b   Lieberman, David A ^c   Falk, Gary W ^d   Vargo, John J ^e   Thota, Prashanti ^e   Sampliner, Richard E ^f   Sharma, Prateek ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF ARIZONA   (United States)

Author keywords

BEST Study; Esophageal Cancer; Intestinal Metaplasia; Screening; Surveillance

Indexed keywords

ADULT; ARTICLE; BARRETT ESOPHAGUS; DISEASE ASSOCIATION; DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT PARTICIPATION; PATIENT REFERRAL; TERTIARY HEALTH CARE;

BARRETT'S ESOPHAGUS; BE; BEST STUDY; CI; CONFIDENCE INTERVAL; EAC; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL CANCER; HGD; HIGH-GRADE DYSPLASIA; INTESTINAL METAPLASIA; LGD; LOW-GRADE DYSPLASIA; NDBE; NONDYSPLASTIC BARRETT'S ESOPHAGUS; NONSTEROIDAL ANTI-INFLAMMATORY DRUG; NSAID; PPI; PROTON PUMP INHIBITOR; SCREENING; SD; STANDARD DEVIATION; SURVEILLANCE;

ADENOCARCINOMA; AGED; BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; FEMALE; HISTOCYTOCHEMISTRY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RISK ASSESSMENT; TERTIARY CARE CENTERS; UNITED STATES;

EID: 84885867786     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.05.007     Document Type: Article

References (26)

1. Pohl H., Welch H.G. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. JNatl Cancer Inst 2005, 97:142-146.
2. Sharma P., McQuaid K., Dent J., et al. Acritical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology 2004, 127:310-330.
3. Wang K.K., Sampliner R.E. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008, 103:788-797.
4. Sharma P. Clinical practice. Barrett's esophagus. NEngl J Med 2009, 361:2548-2556.
5. Spechler S.J., Sharma P., Souza R.F., et al. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology 2011, 140:1084-1091.
6. Sikkema M., de Jonge P.J., Steyerberg E.W., et al. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010, 8:235-244. quiz e32.
7. Jung K.W., Talley N.J., Romero Y., et al. Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett's esophagus: a population-based study. Am J Gastroenterol 2011, 106:1447-1455. quiz 1456.
8. Anderson L.A., Murray L.J., Murphy S.J., et al. Mortality in Barrett's oesophagus: results from a population based study. Gut 2003, 52:1081-1084.
9. Schouten L.J., Steevens J., Huysentruyt C.J., et al. Total cancer incidence and overall mortality are not increased among patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2011, 9:754-761.
10. Thomas T., Abrams K.R., De Caestecker J.S., et al. Meta analysis: cancer risk in Barrett's oesophagus. Aliment Pharmacol Ther 2007, 26:1465-1477.
11. Gatenby P.A., Caygill C.P., Ramus J.R., et al. Short segment columnar-lined oesophagus: an underestimated cancer risk? A large cohort study of the relationship between Barrett's columnar-lined oesophagus segment length and adenocarcinoma risk. Eur J Gastroenterol Hepatol 2007, 19:969-975.
12. Avidan B., Sonnenberg A., Schnell T.G., et al. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol 2002, 97:1930-1936.
13. Yousef F., Cardwell C., Cantwell M.M., et al. The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. Am J Epidemiol 2008, 168:237-249.
14. Weston A.P., Sharma P., Mathur S., et al. Risk stratification of Barrett's esophagus: updated prospective multivariate analysis. Am J Gastroenterol 2004, 99:1657-1666.
15. Weston A.P., Badr A.S., Hassanein R.S. Prospective multivariate analysis of factors predictive of complete regression of Barrett's esophagus. Am J Gastroenterol 1999, 94:3420-3426.
16. Rudolph R.E., Vaughan T.L., Storer B. Segment length and risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med 2000, 133:748.
17. Montgomery E., Bronner M.P., Goldblum J.R., et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol 2001, 32:368-378.
18. Riddell R.H., Goldman H., Ransohoff D.F., et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 1983, 14:931-968.
19. Menke-Pluymers M.B., Hop W.C., Dees J., et al. Risk factors for the development of an adenocarcinoma in columnar-lined (Barrett) esophagus. The Rotterdam Esophageal Tumor Study Group. Cancer 1993, 72:1155-1158.
20. Avidan B., Sonnenberg A., Schnell T.G., et al. Hiatal hernia and acid reflux frequency predict presence and length of Barrett's esophagus. Dig Dis Sci 2002, 47:256-264.
21. Sikkema M., Looman C.W., Steyerberg E.W., et al. Predictors for neoplastic progression in patients with Barrett's esophagus: a prospective cohort study. Am J Gastroenterol 2011, 106:1231-1238.
22. Corley D.A., Kerlikowske K., Verma R., et al. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003, 124:47-56.
23. Nguyen D.M., Richardson P., El-Serag H.B. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology 2010, 138:2260-2266.
24. Vaughan T.L., Dong L.M., Blount P.L., et al. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol 2005, 6:945-952.
25. El-Serag H.B., Aguirre T.V., Davis S., et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 2004, 99:1877-1883.
26. Hillman L.C., Chiragakis L., Shadbolt B., et al. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus. Aliment Pharmacol Ther 2008, 27:321-326.